Cerus Corporation
NASDAQ:CERSMedical - Devices
+$0.08 today
- Market cap
- $391.79M
- Beta
- 1.77
- P/E (TTM)
- -53.8
- EPS (TTM)
- -$0.05
Volume 6.09M
Average 2.33M
CERS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Cerus CorporationNASDAQ: CERS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $14.53M fell 12.5% year over year, behind the +7.6% change in trailing-twelve-month research & development. Sequentially, it fell 11.3% from the prior quarter. Over 3 fiscal years it compounded at +0.8% a year.
Context
- Research & development amounted to 31.9% of revenue in FY2025, down 0.8 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -12.5% toward the trailing-twelve-month pace of +7.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 65.72M USD
- Year-over-year change
- +11.6%
- 4-year CAGR
- +0.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 65.72M | +11.6% |
| FY2024 | 2024-12-31 | 58.91M | -12.9% |
| FY2023 | 2023-12-31 | 67.64M | +5.5% |
| FY2022 | 2022-12-31 | 64.11M | +0.7% |
| FY2021 | 2021-12-31 | 63.69M | — |
Research & Development vs competitors
How CERS compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +7.6% is the 2nd highest of 4, against a peer median of +3.8%.
- Research & development amounts to 29.5% of revenue for CERS, versus a peer median of 4.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €409.96M EUR | +3.8% | -0.3% | 5.5% | |
| LTM Mar 2026 | $65.65M USD | +7.6% | +0.8% | 29.5% | |
| LTM Jun 2026 | $59.46M USD | -4.4% | +0.6% | 4.4% | |
| LTM Jun 2026 | $11.52M USD | +332.9% | +9.6% | 2.2% | |
| Peer median (excluding CERS) | — | +3.8% | +0.6% | 4.4% | |
Competitors are the stored peer set for CERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 130.86M | 162.05M | 156.37M | 180.27M | 206.13M |
| Cost of Revenue | 63.48M | 74.95M | 69.97M | 80.75M | 95.85M |
| Gross Profit | 67.38M | 87.09M | 86.4M | 99.52M | 110.29M |
| Gross Margin | 51.5% | 53.7% | 55.3% | 55.2% | 53.5% |
| Research & Development | 63.69M | 64.11M | 67.64M | 58.91M | 65.72M |
| Selling, General & Admin | 81.29M | 83.34M | 75.52M | 75.89M | 80.91M |
| Operating Expenses | 116.32M | 121.18M | 116.45M | 113.75M | 146.63M |
| Depreciation & Amortization | 3.15M | 2.98M | 2.6M | 1.86M | 2M |
| EBITDA | (45.99M) | (33.52M) | (26.34M) | (10.02M) | (4.94M) |
| EBITDA Margin | -35.1% | -20.7% | -16.8% | -5.6% | -2.4% |
| Operating Income | (48.94M) | (34.08M) | (30.05M) | (14.23M) | (36.35M) |
| Operating Margin | -37.4% | -21.0% | -19.2% | -7.9% | -17.6% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 4.92M | 5.83M | 8.39M | 8.88M | 8.34M |
| Other Income / Expenses | (5.12M) | (8.26M) | (7.27M) | (6.53M) | 21.06M |
| Income Before Tax | (54.06M) | (42.34M) | (37.32M) | (20.76M) | (15.28M) |
| Pre-Tax Margin | -41.3% | -26.1% | -23.9% | -11.5% | -7.4% |
| Income Tax Expense | 319K | 488K | 325K | 205K | 354K |
| Net Income | (54.37M) | (42.78M) | (37.49M) | (20.92M) | (15.63M) |
| Net Margin | -41.6% | -26.4% | -24.0% | -11.6% | -7.6% |
| EPS (Basic) | (0.32) | (0.24) | (0.21) | (0.11) | (0.08) |
| EPS (Diluted) | (0.32) | (0.24) | (0.21) | (0.11) | (0.08) |
| Weighted Avg Shares | 171.28M | 176.55M | 180.27M | 184.56M | 190.59M |
| Weighted Avg Shares (Diluted) | 171.28M | 176.55M | 180.27M | 184.56M | 190.59M |
Cerus Corporation
NASDAQ:CERS
Intrinsic Alpha fair value
Locked
Current Price
$1.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.